Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot may shield transplant patients from deadly immune attack

NCT ID NCT04686929

Prevention Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called abatacept, given as a shot under the skin, to prevent a serious complication called graft-versus-host disease (GVHD) in 29 adults with blood cancers. Participants received a stem cell transplant from a half-matched donor. The goal was to see if abatacept could safely lower the risk of GVHD without causing major side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

29 people

The number who actually took part.

Started

Jun 2021

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age≧18 years 2. ECOG score 0-2 / Karnofsky score≧80 3. haplo-HCT is proposed 4. Conditioning with motified Bu/Cy+ATG regimen 5. Having the following hematologic malignancies with transplant indications: 1. Acute leukemia 2. Myelodysplastic syndrome 3. Aggressive lymphoma 6. Expected survival ≥ 3 months 7. Written informed Consent can be acquired 8. Agree to use effective contraception Exclusion Criteria: 1. With a history of allo-HCT previously 2. Allergic/intolerant to Abatacept 3. Contraindications to the use of Abatacept 4. HIV infection, or active HBV infection or HCV infection 5. Uncontrolled active infection 6. Vital organ function intolerated to transplantation 7. Other malignancies except for the following diseases: malignant tumors that have been cured for at least 3 years without active lesions; adequete treated non-melanoma skin cancer, malignant amygdala, and carcinoma in situ without active lesions 8. Evidence of complications or medical conditions that may interfere with research or put the subjects at serious risk, including but not limited to severe cardiovascular disease (e.g. New York Heart Association grade III or IV heart disease, myocardial infarction in the past 6 months, unstable arrhythmia or unstable angina) and/or severe lung disease (e.g. history of severe obstructive lung disease and symptomatic bronchospasm) 9. Pregnant and lactational women 10. Any life-threatening disease, medical condition, or organ dysfunction unfit for participants, or may interfere with the absorption or metabolism of Abatacept

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abatacept are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute leukemia aggressive B-cell non-Hodgkin lymphoma myelodysplastic syndrome acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abatacept Acute-graft-versus-host disease Haplo-identical HCT Prevention

Contacts and locations

Locations

  • the First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.